Cargando…
Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts
Imatinib, an inhibitor of PDGF-Rβ and other tyrosine kinase receptors, has been shown to decrease microvessel density and interstitial fluid pressure in solid tumours, thereby improving subsequent delivery of small molecules. The purpose of this study was to test whether pretreatment with imatinib i...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2007
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360385/ https://www.ncbi.nlm.nih.gov/pubmed/17712313 http://dx.doi.org/10.1038/sj.bjc.6603941 |